Trends & Analysis

#Biotechnology #Drug development #Drug discovery #Genomics #Synthetic biology #Synthetic DNA

Synthetic biology: Shaping the future of drug discovery 

By Lu Rahman  There are some exciting developments happening in synthetic biology and as a result the sector is highly attractive from an investment perspective. Using synthetic DNA to develop drugs and to better understand the toxic effects of them is a key driver for this market. BCC Research… Read More

#Exclusive Content #Trends & Analysis

Genomics
#Biotechnology #Comment #Data #Gene editing #Genetics / genomics #Genome sequencing #Healthcare #Public health #Research #Whole genome sequencing

Why genomic healthcare data matters in the development of new therapies 

Genomic healthcare data is critical to identify disease risk, ancestry, traits and response to medicines and aids in the development of new targeted therapies – precision medicines. DDW’s Megan Thomas observes developments of accessibility in this sector and the potential impact.  The origins  One might… Read More

#Exclusive Content #Opinion #Trends & Analysis

#Biotechnology #Drug discovery #Life sciences #Pharmacology

What’s interesting about Australian drug discovery? 

Australia’s drug discovery industry shows promise and innovation, as well as business opportunities. DDW’s Megan Thomas takes a look at some of the reasons why we should be keeping an interested eye on the developments coming out of this country.   The Sector Snapshot 2022: Expansion is continuous … Read More

#Exclusive Content #Market Reports #Trends & Analysis

Japanese flag
#Biopharmaceutical #Collaboration #Drug discovery #Healthcare #Investment #Life sciences #Market reporting #Start-ups

A review of Japan’s drug discovery landscape  

DDW Multimedia Editor Megan Thomas takes a broad look at the drug discovery and development landscape in Japan and highlights how it is bolstered by government policies, investment, collaboration, start-up ecosystems and academic research.   Japan continues to be one of the largest pharmaceutical markets in the world,… Read More

#Business & Investment #Editor's Choice #Exclusive Content #Market Reports #Trends & Analysis

#Biopharma #Digitalisation #Regulatory

The next steps for biopharma regulations

Following a decade of solid groundwork to modernise regulatory information management in life sciences, leading companies have now shifted their focus to how they might exploit this new digital landscape – to transform process management; improve data exchange with the enterprise at large; revisit organisational structures… Read More

#Exclusive Content #Regulatory #Trends & Analysis

#Clinical development #Immunology / Virology & Vaccines #Infectious diseases #mRNA #Public health

mRNA technology may hold the future for a cytomegalovirus vaccine 

Listen to this article on the DDW podcast: Allison August, M.D., Vice President, Clinical Development, Infectious Diseases at Moderna examines the data on cytomegalovirus (CMV), why attempts at vaccines for CMV have so far proved elusive and the emerging options to address this unmet need. … Read More

#Exclusive Content #Trends & Analysis

#AI / data analytics / healthtech / informatics #Biopharmaceuticals #Drug discovery #Healthcare

How AI in pharma can live up to the hype 

Listen to this article on the DDW Podcast: Ben Folwell, Principal Consultant at Citeline, maps out how AI, swarm learning and open access to clinical data could revolutionise drug discovery.  Artificial intelligence (AI) is notorious for its industry hype, touted to revolutionise the way multiple sectors… Read More

#Business & Investment #Exclusive Content #Opinion #Trends & Analysis

#AI #Machine learning #Software

AI in R&D: From hot topic to practical application 

This paid-for advertorial by Benchling appeared in the DDW ebook – AI in drug discovery: How technology is driving innovation. By Ashoka Rajendra, Head of Development & Manufacturing Products at Benchling Artificial Intelligence (AI) is emblematic of the new era of modern biotech — data-driven, collaborative and ultimately,… Read More

#Business & Investment #Exclusive Content #Opinion #Trends & Analysis

#AI #AI / data analytics / healthtech / informatics #Machine learning #Pharma

Intelligent designs: How pharma researchers are using AI 

DDW Editor Reece Armstrong explores how AI is being utilised in the lab and what the technology can really do within pharma.  Artificial intelligence (AI), a branch of computer science encompassing machine learning and deep learning, and which technologies such as automation, natural language processing… Read More

#Business & Investment #Exclusive Content #Opinion #Trends & Analysis

#Cell and gene therapy #Covid-19 #Drug discovery #Manufacturing

The challenges and trends of cell & gene therapies 

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year.   There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. This area of medicine,… Read More

#Exclusive Content #Opinion #Trends & Analysis

#AI / data analytics / healthtech / informatics #Covid-19 #Machine learning #SLAS Europe

A different future is possible with the right data

Listen to this article on the DDW Podcast: Philip Gribbon is Head of Discovery Research at the Fraunhofer Institute for Translational Medicine and Pharmacology in Hamburg, Germany. Ahead of his participation in a Data Sharing panel at SLAS Europe 2022, Gribbon tells Megan Thomas about the importance and lasting… Read More

#Exclusive Content #Opinion #Trends & Analysis